Breaking News

Trials & Filings in Brief: Nov. 21, 2013

By Gil Roth | November 21, 2013

Forest Labs, Gedeon Richter, GSK, Lundbeck, Nanotherapeutics, Otsuka, Pfizer,

Phase I
Pfizer, GSK study combo for melanoma . . . read more

Forest, Richter Schizophrenia Drug Gets CRL . . . read more

Nanotherapeutics meets with FDA over vax-facility . . . read more

Otsuka, Lundbeck monthly Abilify approved in Europe . . . read more
  • Predictive Analytics and the Future of RBM

    Rajneesh Patil, Senior Director, RBM and Analytics, QuintilesIMS||January 23, 2017
    How advances in Risk-Based Monitoring will enable a more proactive approach to identify and mitigate potential risks

  • The Growing Realm of Real-World Data

    Kristin Brooks, Contract Pharma||November 8, 2016
    PPD's Evidera acquisition aims to help clients address the growing demand for evidence from regulators and payers

  • Mastering Immunotherapy Clinical Trials: Dosing and Response

    Mastering Immunotherapy Clinical Trials: Dosing and Response

    Kristin Brooks, Contract Pharma||August 1, 2016
    Andrew Zupnick of Novella Clinical provides insights into dosing and measuring response in immunotherapy clinical trials